📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 12:44
631 analysed today
631
Today
134,273
All-time analysed
40,194
Positive
6,287
Negative
79,947
Neutral
7,777
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Wanbury Receives EDQM Approval for Rivaroxaban API and USFDA DMF Clearances
Wanbury Limited has received approval from the European Directorate for the Quality of Medicines (EDQM) for its new Rivaroxaban API, enabling sales in the EU and other CEP-accepting markets. Additionally, the company secured USFDA DMF clearances for Paroxetine HCl and Metformin HCl. These approvals are critical as approximately 65% of Wanbury's export revenue is dependent on maintaining USFDA and EDQM compliance. The clearances support the company's ongoing ANDA reviews for multiple customers, potentially driving volume growth in regulated markets.
Confidence: HIGH
What changedWanbury has successfully cleared regulatory hurdles for a new product (Rivaroxaban) in Europe and updated its regulatory filings for two key products in the US market.
Why it mattersFor a company with 65% of export revenue tied to regulatory compliance, these approvals de-risk the portfolio and provide a pathway for volume growth in high-margin regulated markets like the US and EU.
Metformin Annual Capacity: 8,500 tonsExport Revenue at Regulatory Risk: 65%TTM Revenue: ₹629 crCumulative Reactor Capacity: 386 KLDebt-to-Equity Ratio: 1.54
📅 Short termThe news is likely to be viewed positively by the market as it validates the company's R&D and regulatory capabilities, reducing immediate compliance concerns.
📈 Long termSupports Wanbury's long-term strategy of commercializing 4 new molecules annually and expanding its footprint in regulated markets to improve its 13.9% OPM.
⚠ Risk flags
- High leverage (D/E 1.54)
- High concentration of revenue (65%) dependent on continuous regulatory compliance
Key Highlights
Received EDQM approval for new product Rivaroxaban API for European markets
Obtained USFDA DMF clearances for Paroxetine HCl and Metformin HCl
Regulatory compliance protects the 65% of export revenue derived from stringent markets
Supports the company's global leadership in Metformin, where it has 8,500 tons/year capacity
Clearances coincide with ongoing ANDA reviews for multiple international customers
👀 What to Watch
Watch for the commercial launch timeline of Rivaroxaban in Europe and the conversion of pending ANDA reviews into active supply orders from US customers.
Wanbury Q1 PAT Falls 76% to ₹3.2 Cr; ₹205 Cr Debt Refinanced and Promoter Pledge Released
Wanbury reported a weak Q1 FY27 with PAT declining 76% YoY to ₹3.2 Cr, primarily due to a 517 bps contraction in EBITDA margins caused by rising solvent and crude-linked input costs. Despite the earnings miss, the company achieved a major structural milestone by refinancing ₹205 Cr of debt, reducing interest rates from 12.5% to sub-10% effective July 2026. This refinancing also resulted in the release of pledges on 40.65% of the company's total equity, significantly improving the promoter's holding profile. Regulatory progress remained strong with successful inspections by Australian and Korean agencies.
Confidence: HIGH
What changedWanbury's operational profitability was hit by transitory input cost spikes, but its balance sheet and promoter risk profile improved significantly through debt refinancing and pledge release.
Why it mattersThe release of a 40.65% equity pledge removes a major market overhang, while the interest rate reduction on ₹205 Cr debt (approx. 25% of market cap) will provide a recurring boost to net profitability from Q2 FY27 onwards.
PAT Growth (YoY): -76.0%Debt Refinanced: ₹205 CrPledge Released (% of Equity): 40.65%Interest Rate Reduction: 250+ bpsEBITDA Margin: 10.0%
📅 Short termThe sharp decline in PAT and margins may cause short-term price volatility, though the pledge release is a strong positive counter-signal.
📈 Long termStructural improvements in debt costs, regulatory approvals for new markets (Australia/Korea), and upcoming capacity in Andhra Pradesh suggest a positive long-term trajectory if margins normalize.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High sensitivity to crude-linked solvent prices
- Logistics disruptions in West Asia impacting API exports
- High leverage (D/E 1.54)
Key Highlights
PAT dropped 76% YoY to ₹3.2 Cr from ₹13.5 Cr, with EPS falling to ₹0.93 from ₹4.12.
EBITDA margins contracted to 10.0% from 15.2% YoY due to West Asia crisis-linked raw material inflation.
Refinanced ₹205 Cr debt with Axis Finance and Poonawalla Fincorp, lowering borrowing costs by over 250 bps.
Released pledge on 1.42 Cr shares, representing 40.65% of total equity and 94.51% of promoter holding.
Patalganga facility cleared Korean MFDS inspection with zero observations; Tanuku site cleared Australian TGA.
👀 What to Watch
Monitor the recovery of EBITDA margins in Q2 FY27 as the company attempts to pass on input cost increases. Track the reduction in finance costs in the next quarterly statement and the commercialization timeline of the new manufacturing block in Andhra Pradesh.
Wanbury Refinances ₹205 Cr Debt, Releases 85.2 Lakh Pledged Shares; Q1 PAT at ₹3.24 Cr
Wanbury Limited reported a weak Q1 FY27 with PAT falling to ₹3.24 Cr from ₹13.49 Cr YoY. However, the company executed a major financial restructuring, refinancing ₹205 Cr of high-cost debt through NBFCs, which led to the release of 85.20 lakh pledged promoter shares on July 7, 2026. Operationally, the company cleared TGA Australia and MFDS-Korea inspections with zero observations. The Board also re-appointed Mohan Kumar Rayana as Whole-time Director for a five-year term starting August 21, 2026.
Confidence: HIGH
What changedThe company has restructured its debt profile, cleared major international regulatory hurdles, and secured its leadership for the next five years.
Why it mattersThe refinancing of ₹205 Cr (nearly equal to the total debt of ₹224 Cr) and the release of promoter pledges significantly reduce financial risk and improve market perception, despite a weak earnings quarter.
Q1 PAT: ₹3.24 CrDebt Refinanced: ₹205 CrPledged Shares Released: 85,20,330 unitsRefinance vs TTM Revenue: 32.6%Refinance vs Market Cap: 24.9%
📅 Short termThe stock may face pressure due to the YoY decline in PAT, but the pledge release and zero-observation regulatory clearances provide a positive counter-narrative.
📈 Long termThe reduction in high-cost debt and successful regulatory audits for export markets (Australia/Korea) strengthen the structural growth path for the API business.
⚠ Risk flags
- High YoY earnings volatility
- High leverage (D/E 1.54) despite refinancing
- Regulatory compliance risk for 65% of export revenue
Key Highlights
Q1 FY27 PAT stood at ₹3.24 Cr, a significant decline from ₹13.49 Cr in the year-ago period.
Refinanced ₹205 Cr of high-cost debt (representing ~32% of TTM revenue) to improve interest coverage and fund capex.
Released 85,20,330 pledged promoter shares following the repayment of existing high-cost borrowings.
Cleared regulatory inspections from TGA Australia and MFDS-Korea with zero observations at two API facilities.
Re-appointed Mohan Kumar Rayana as Whole-time Director for a 5-year term effective August 21, 2026.
👀 What to Watch
Investors should monitor the reduction in finance costs in upcoming quarters following the ₹205 Cr refinancing and watch for the commercialization of the new anaesthetic molecule in Q4 FY26.
27,530 ESOP Shares Allotted; Mohan Kumar Rayana Re-appointed as Whole-time Director for 5 Years
Wanbury Limited's board approved the unaudited financial results for the quarter ended June 30, 2026. The company also allotted 27,530 equity shares to employees under its 2016 ESOP plan at an exercise price of Rs 10 per share, resulting in a negligible equity dilution of approximately 0.08%. Furthermore, Mr. Mohan Kumar Rayana was re-appointed as Whole-time Director for a five-year term effective August 21, 2026, ensuring leadership continuity. The total money realized from the ESOP exercise was Rs 2.75 lakh.
Confidence: HIGH
What changedThe company has updated its share capital following an ESOP exercise and confirmed the continuation of a key executive director for another five years.
Why it mattersWhile the ESOP allotment is minor, the re-appointment of a director associated with the company since 1988 provides management stability as the firm targets new molecule launches and market expansion in China and Brazil.
ESOP Allotment: 27,530 sharesExercise Price: Rs 10New Paid-up Capital: Rs 34,96,69,280Director Term: 5 yearsESOP Dilution: ~0.08%
📅 Short termThe stock may see minor movement based on the underlying Q1 financial performance details, though the administrative announcements (ESOP/Director) are neutral.
📈 Long termFocus remains on the company's ability to scale its API business (Metformin/Sertraline) and manage its high leverage while navigating USFDA/EDQM regulatory requirements.
⚠ Risk flags
- High leverage (Gearing 3.25x in FY25)
- Regulatory risk (65% of export revenue dependent on USFDA/EDQM compliance)
Key Highlights
Allotment of 27,530 equity shares of Rs 10 face value following ESOP exercise
Paid-up share capital increased to Rs 34.97 Cr from Rs 34.94 Cr
Re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a 5-year term
Total money realized from the ESOP exercise amounted to Rs 2,75,300
Board meeting concluded after 4 hours of deliberation (3:30 PM to 7:30 PM)
👀 What to Watch
Investors should review the detailed Q1 FY27 financial statements to assess if the 10.6% expected growth rate is being maintained and monitor the company's progress on debt reduction given its high D/E ratio of 1.54.
Wanbury Receives USFDA 'No DMF Deficiency' Letter for Metformin HCl API
Wanbury Limited has received a 'No DMF deficiency letter' from the USFDA for multiple Abbreviated New Drug Applications (ANDAs) that utilize its Metformin HCl API. This is a critical regulatory milestone as the company is the world's largest manufacturer of Metformin with a capacity of 8,500 tons per year. Maintaining USFDA compliance is vital for Wanbury, as approximately 65% of its export revenue is dependent on adherence to stringent regulatory standards. The company also confirmed expansion into the South Korean market with a new DMF filing for another API.
Confidence: HIGH
What changedThe USFDA has confirmed that there are no deficiencies in the Drug Master File (DMF) for Wanbury's Metformin HCl API used in several customer drug applications.
Why it mattersThis ensures uninterrupted supply to the US market for Wanbury's core product. Given the company's high debt-to-equity ratio of 1.54, maintaining steady cash flows from its primary API business is essential for financial stability.
Metformin Capacity: 8,500 tons/yearExport Revenue Dependency: 65%TTM Revenue: ₹629 CrDebt-to-Equity Ratio: 1.54Reactor Capacity: 386 KL
📅 Short termThe news provides regulatory clarity and reduces risk, likely supporting the stock's recent positive momentum (48.8% return over 6 months).
📈 Long termSustained compliance and expansion into markets like South Korea and China are structural positives for scaling the API business beyond Metformin.
⚠ Risk flags
- High leverage (Gearing 3.25x in FY25)
- High concentration risk on regulatory approvals for export revenue
Key Highlights
Received 'No DMF deficiency letter' from USFDA for multiple ANDAs using Metformin HCl API
Metformin capacity stands at 8,500 tons per year, making Wanbury the largest global manufacturer
Regulatory compliance protects 65% of export revenue which relies on USFDA/EDQM approved sites
Expanded business footprint into South Korea by filing a DMF for an additional API
Maintains cumulative reactor capacity of 386 KL across two USFDA-approved facilities
👀 What to Watch
Investors should monitor the progress of the South Korean market entry and the scheduled launch of the new Anaesthetic product in Q4 FY26.
USFDA Issues Form 483 with 6 Observations for Tanuku Facility
Wanbury Limited's API facility at Tanuku, Andhra Pradesh, underwent a routine USFDA inspection from July 13 to July 17, 2026. The inspection concluded with the issuance of a Form 483 containing six observations. While the company states these observations are addressable and do not expect a material impact on operations, regulatory compliance is critical as 65% of the company's export revenue is tied to USFDA-approved sites.
Confidence: HIGH
What changedA routine USFDA inspection at a key API facility resulted in six procedural or compliance observations (Form 483).
Why it mattersRegulatory compliance is the primary operational risk for Wanbury; any failure to resolve USFDA observations could halt exports to regulated markets, which are essential for its TTM revenue of ₹629 Cr.
USFDA Observations: 6Inspection Period: July 13-17, 2026Export Revenue at Risk: 65%TTM Revenue: ₹629 Cr
📅 Short termThe stock may face some pressure due to the uncertainty surrounding the nature of the 6 observations until the company provides further clarity on the remediation plan.
📈 Long termIf resolved within the stipulated time, this remains a routine regulatory event. However, persistent issues could delay the launch of 4 new molecules planned per year starting FY27.
⚠ Risk flags
- Regulatory non-compliance risk
- High leverage (D/E 1.54)
- Concentration of export revenue on USFDA-approved sites
Key Highlights
Routine cGMP inspection conducted by USFDA over 5 days from July 13 to July 17, 2026.
USFDA issued a Form 483 with 6 observations at the conclusion of the audit.
Company maintains that 65% of export revenue depends on maintaining USFDA/EDQM compliance.
Management expects no material impact on financial performance or manufacturing operations.
The facility is located at Tanuku, West Godavari District, Andhra Pradesh.
👀 What to Watch
Investors should monitor the classification of these observations by the USFDA (NAI, VAI, or OAI). A 'Voluntary Action Indicated' (VAI) would be neutral, but an 'Official Action Indicated' (OAI) could lead to a Warning Letter, potentially impacting the 65% export revenue stream.
6 USFDA observations issued for Wanbury's Tanuku facility following routine inspection
Wanbury Limited completed a routine USFDA inspection at its Tanuku facility in Andhra Pradesh, conducted from July 13 to July 17, 2026. The regulator issued a Form 483 with six observations at the conclusion of the audit. This is a material development as the company's internal risk assessments indicate that 65% of its export revenue depends on maintaining compliance at USFDA-approved sites. The company has stated it will respond to these observations within the stipulated timeframe.
Confidence: HIGH
What changedA routine USFDA audit at the Tanuku API facility concluded with the issuance of a Form 483 containing six observations.
Why it mattersMaintaining USFDA approval is critical for Wanbury's API business; any regulatory escalation could jeopardize a significant portion of its ₹629 Cr TTM revenue and its ability to service ₹224 Cr in debt.
Observations: 6Export Revenue Exposure: 65%TTM Revenue: ₹629 CrDebt-to-Equity: 1.54Metformin Capacity: 8,500 tons/year
📅 Short termThe stock may experience volatility in the coming weeks as the market awaits clarity on the nature and severity of the 6 observations.
📈 Long termSuccessful resolution is essential for the company's long-term growth strategy, which includes launching 4 new molecules annually and expanding into China and Brazil.
⚠ Risk flags
- Regulatory non-compliance risk
- High financial leverage (D/E 1.54)
- High revenue concentration in USFDA-regulated markets
Key Highlights
USFDA inspection conducted over a 5-day period from July 13 to July 17, 2026
Issuance of Form 483 containing 6 observations regarding manufacturing practices
Regulatory compliance at USFDA sites critical for 65% of total export revenue
Company operates 2 USFDA-approved facilities with a cumulative reactor capacity of 386 KL
Wanbury is the world's largest Metformin manufacturer with 8,500 tons/year capacity
👀 What to Watch
Monitor for management updates regarding the severity of the 6 observations and whether the USFDA classifies the final report as VAI (Voluntary Action Indicated) or OAI (Official Action Indicated).
₹180 Cr Early Redemption of 12.5% High-Cost NCDs by Wanbury
Wanbury Limited has approved the full early redemption of its 12.5% secured, unlisted Non-Convertible Debentures (NCDs) with an outstanding principal of ₹180 Cr. This move targets a significant portion of the company's total debt (₹224 Cr) and is being executed well ahead of the original February 2030 maturity. The high interest rate of 12.5% suggests that this redemption will lead to substantial interest cost savings, potentially improving net margins.
Confidence: HIGH
What changedThe company is voluntarily settling its entire outstanding high-interest NCD obligation of ₹180 Cr before its 2030 maturity.
Why it mattersThis is a major de-leveraging event. Given the company's net worth of ₹145 Cr, redeeming ₹180 Cr of debt significantly improves the debt-to-equity ratio (previously 1.54) and reduces annual interest outgo by approximately ₹22.5 Cr.
Outstanding Principal: ₹180 CrInterest Rate: 12.5%Redemption vs Net Worth: ~124%Redemption vs Total Debt: ~80.3%Original Maturity: February 28, 2030
📅 Short termPositive market sentiment is expected as the company reduces its high-interest burden and improves its balance sheet health.
📈 Long termStructural improvement in profitability and cash flows due to lower interest expenses; strengthens the company's financial position for future expansions.
⚠ Risk flags
- Source of funds for redemption not explicitly disclosed in this filing
- Potential liquidity tightening if funded entirely through internal accruals
Key Highlights
Full redemption of ₹180 Cr outstanding principal from an initial issue size of ₹200 Cr.
Elimination of high-cost debt carrying a 12.5% interest rate, which was a drag on profitability.
Redemption is being executed years ahead of the scheduled maturity date of February 28, 2030.
The outstanding amount of ₹180 Cr represents approximately 80% of the company's total debt of ₹224 Cr.
Record date for the early redemption was set as June 20, 2026.
👀 What to Watch
Investors should monitor the upcoming quarterly results to see the reduction in finance costs and verify the source of funds used for this redemption (internal accruals vs. refinancing).
Wanbury FY26 EBITDA hits record ₹108 Cr; Debt reduced by 75% from peak
Wanbury Limited reported a strong financial turnaround in its FY26 investor presentation, achieving its highest-ever operational EBITDA of ₹108 Cr. The company has successfully reduced its debt by approximately 75% from a peak of ₹700 Cr and lowered its borrowing costs from 22.5% to 12.5% effective March 2025. The API segment continues to dominate, contributing 88% of the ₹650 Cr FY26 revenue, supported by a 30% global market share in Sertraline. Notably, the Formulations business reached financial break-even in FY26, marking a significant operational milestone.
Confidence: HIGH
What changedWanbury has transitioned from a debt-restructuring phase to a growth phase, characterized by record operational profits and a leaner balance sheet.
Why it mattersThe reduction in interest rates by 1,000 basis points and the break-even of the formulations business significantly improve the company's cash flow profile and ability to fund brownfield expansions.
FY26 Total Revenue: ₹650 CrOperational EBITDA: ₹108 CrBorrowing Cost Reduction: 10.0%Sertraline Global Market Share: 30%Cumulative Reactor Capacity: 386 KL
📅 Short termThe market is likely to react positively to the record EBITDA and the successful debt refinancing which improves bottom-line visibility.
📈 Long termThe structural turnaround is complete; long-term growth will be driven by the planned 4 new molecule launches annually and expansion into the China and Brazil markets.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory risk: 65% of export revenue depends on USFDA/EDQM compliance
- High leverage: Gearing remains a factor despite recent debt reductions
Key Highlights
Achieved highest-ever operational EBITDA of ₹108 Cr in FY26
Reduced debt by ~75% from peak obligations of ₹700 Cr
Borrowing costs reduced from 22.5% to 12.5% effective March 1, 2025
Maintains ~30% global market share in Sertraline and ~10% in Metformin
Formulations business achieved financial break-even in FY26 with ₹76 Cr revenue
👀 What to Watch
Watch for the execution of the new product pipeline, specifically the launch of 4 new molecules per year starting FY27, and the impact of lower interest costs on net profit margins.
Wanbury to Incorporate Skin Health Subsidiary with 82% Stake; Appoints EY as Internal Auditor
Wanbury Limited has approved the incorporation of a new subsidiary, Wanbury Skin Health Limited, to expand its presence in the pharmaceutical industry. The company will hold an 82% stake in the new entity with an initial investment of ₹4.10 lakh for 41,000 equity shares. Additionally, the board has appointed Ernst & Young LLP as the Internal Auditor and ABK & Associates as the Cost Auditor for FY 2026-27. These steps reflect a strategic move into specialized healthcare segments and a commitment to strengthening internal governance.
Key Highlights
Incorporation of a new subsidiary, Wanbury Skin Health Limited, with an 82% majority stake.
Initial capital investment of ₹4,10,000 for 41,000 equity shares at ₹10 face value.
Appointment of Big 4 firm Ernst & Young LLP as Internal Auditor for the 2026-27 financial year.
Appointment of ABK & Associates as Cost Auditor for FY 2026-27.
Strategic focus on the pharmaceutical and skin health industry for future growth.
👀 What to Watch
Investors should monitor the development of the new skin health vertical as it could be a growth driver. The appointment of a top-tier internal auditor like EY is a positive signal for corporate governance and risk management.
Wanbury to Incorporate New Subsidiary 'Wanbury Skin Health' with 82% Stake
Wanbury Limited has approved the incorporation of a new subsidiary, proposed to be named Wanbury Skin Health Limited, focusing on the pharmaceutical industry. The company will invest an initial capital outlay of ₹4,10,000 to acquire an 82% stake, comprising 41,000 equity shares at ₹10 each. In a move to strengthen governance, the board also appointed Ernst & Young LLP (EY) as the Internal Auditor for FY 2026-27. This expansion suggests a strategic entry or focused push into the dermatology and skin care segment.
Key Highlights
Approved incorporation of 'Wanbury Skin Health Limited' as an 82% owned subsidiary in India.
Initial investment of ₹4.10 lakh for 41,000 equity shares at a face value of ₹10 each.
Appointment of Ernst & Young LLP as Internal Auditor for the Financial Year 2026-2027.
Appointment of ABK & Associates as Cost Auditor for the Financial Year 2026-2027.
The new entity will operate within the pharmaceutical industry, specifically targeting the skin health segment.
👀 What to Watch
Investors should watch for further disclosures regarding the product pipeline and business plan of the new skin health subsidiary. The appointment of a 'Big Four' firm like EY for internal audits is a positive sign for corporate governance.
Wanbury to Incorporate 'Wanbury Skin Health' Subsidiary; Appoints EY as Internal Auditor
Wanbury Limited has approved the incorporation of a new subsidiary, Wanbury Skin Health Limited, in which it will hold an 82% stake. The initial investment is modest at ₹4.10 lakh, representing 41,000 equity shares at face value. In a significant governance move, the company has also appointed Ernst & Young LLP (EY) as its Internal Auditor for the financial year 2026-27. Additionally, ABK & Associates has been appointed as the Cost Auditor for the same period.
Key Highlights
Incorporation of new subsidiary 'Wanbury Skin Health Limited' with 82% shareholding
Initial capital outlay of ₹4,10,000 for 41,000 equity shares at ₹10 each
Appointment of Big 4 firm Ernst & Young LLP as Internal Auditor for FY 2026-27
Appointment of ABK & Associates as Cost Auditor for FY 2026-27
Strategic expansion into the specialized pharmaceutical segment of skin health
👀 What to Watch
Investors should view the entry into the skin health segment as a positive niche expansion and the appointment of EY as a step toward improved corporate governance. Monitor future capital allocations to this new subsidiary to gauge the scale of the venture.
Wanbury Refinances Debt: Interest Rate Cut to Sub 10% and 40.65% Equity Pledge Released
Wanbury Limited has successfully refinanced its existing debt facilities through Axis Finance Limited and Poonawala Fincorp. This refinancing has led to a significant reduction in the company's borrowing cost from 12.5% per annum to below 10% per annum, effective July 1, 2026. Consequently, a massive pledge on 1,42,03,818 equity shares (representing 40.65% of the total paid-up capital) held by the Promoter Group has been released. Following this, only 5.49% of the Promoter Group's holding remains pledged for working capital purposes.
Key Highlights
Debt facilities taken over by Axis Finance and Poonawala Fincorp from Investec AIF and Tata Capital.
Interest rate reduced from 12.5% p.a. to Sub 10% p.a., effective July 1, 2026.
Release of pledge on 1.42 crore shares, which accounts for 94.51% of the total Promoter Group holding.
Total unencumbered equity increased by 40.65% of the company's total paid-up share capital.
Expected reduction in finance costs to directly support and improve future profitability.
👀 What to Watch
Investors should view this as a highly positive development as it reduces financial risk and improves the bottom line; the stock may see a re-rating due to the massive reduction in promoter pledge.
Wanbury Tanuku Site Clears TGA Australia Inspection; Patalganga Site Gets Korean FDA GMP
Wanbury Limited's API manufacturing facility in Tanuku, Andhra Pradesh, has successfully cleared a quality inspection by Australia's Therapeutic Goods Administration (TGA). Once the formal GMP certificate is received, the company will be authorized to export 3 additional APIs to the Australian market. Additionally, the company's Patalganga site has secured a GMP certificate from the Korean FDA (MFDS) following an inspection in April 2026. These regulatory milestones enhance the company's global compliance standing and facilitate market expansion in regulated territories.
Key Highlights
Successful completion of TGA (Australia) quality inspection at the Tanuku API manufacturing site
Receipt of TGA GMP certificate will enable the shipment of 3 additional APIs to Australia
Patalganga site received GMP certification from MFDS (Korean FDA) for an April 2026 inspection
Reinforces company's cGMP compliance and commitment to international quality standards
👀 What to Watch
Investors should monitor the formal receipt of the TGA certificate and the subsequent impact on export volumes. The dual regulatory clearances in Australia and Korea provide a positive outlook for the company's international API business.
Wanbury Submits DMFs for New APIs; Korea FDA Clears Patalganga Plant with Zero Observations
Wanbury Limited has announced a strategic expansion in international markets by submitting Drug Master Files (DMFs) for Diphenhydramine HCl in Malaysia and Singapore. Additionally, the company is targeting Korea and Latin America for Paroxetine HCl through new DMF submissions. A significant regulatory milestone was achieved as the MFDS (Korea FDA) issued a formal audit report for the Patalganga facility with zero observations following an inspection in April 2026. These moves strengthen the company's API export pipeline and validate its manufacturing compliance standards.
Key Highlights
Submitted DMF for Diphenhydramine HCl to regulatory bodies in Malaysia and Singapore.
Targeting market entry for Paroxetine HCl in Korea and Latin America via new DMF filings.
Received formal audit report from MFDS (Korea FDA) for the Patalganga manufacturing facility.
The MFDS inspection conducted in April 2026 concluded with zero observations, confirming high compliance.
Expansion into new geographies aims to diversify and grow the global API revenue stream.
👀 What to Watch
Investors should view the zero-observation audit report as a strong indicator of manufacturing quality, which reduces regulatory risk. Monitor the progress of these DMF filings as they are precursors to potential volume growth in the international API segment.
Wanbury FY26 PAT Surges 117% to ₹66.1 Cr; EPS More Than Doubles to ₹20.55
Wanbury Limited reported a robust full-year performance for FY26, with PAT growing 116.6% YoY to ₹66.1 crore and EBITDA margins expanding 330 bps to 16.5%. While Q4 FY26 revenue saw a slight 4.3% YoY decline to ₹164.6 crore due to export disruptions from the West Asia crisis, the company still achieved a 7.2% YoY growth in quarterly PAT. Operational highlights include the launch of a new Anaesthetic API and receiving zero observations from the MFDS (Korea) regulatory inspection. The company's EPS significantly improved to ₹20.55 from ₹9.32 in the previous fiscal year.
Key Highlights
FY26 PAT grew by 116.6% YoY to ₹66.1 Cr, with PAT margins expanding by 509 bps to 10.2%.
Full-year EBITDA increased 34.9% YoY to ₹107.7 Cr, driven by better product mix and procurement efficiencies.
Q4 FY26 gross margin expanded by 887 bps YoY to 60.4% despite geopolitical revenue headwinds in March.
Successfully launched new Anaesthetic API from Tanuku facility with commercial dispatches to Europe starting Feb 2026.
Maintained a strong regulatory track record with zero observations in MFDS (Korea), USFDA, and ANVISA (Brazil) inspections.
👀 What to Watch
Investors should note the significant bottom-line growth and margin expansion, which suggest improved operational efficiency. The temporary Q4 revenue dip appears linked to external geopolitical factors rather than fundamental weakness, making the strong full-year EPS growth the primary focus.
Wanbury FY26 Net Profit Surges 116% to ₹66.13 Crore; Revenue Up 8.5%
Wanbury Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with net profit more than doubling to ₹66.13 crore from ₹30.53 crore in FY25. Annual revenue grew 8.5% to ₹650.27 crore, driven by steady operations. A key highlight is the 18.9% reduction in finance costs to ₹29.98 crore, suggesting improved financial health and debt management. Q4FY26 profit also showed strength at ₹21.70 crore, despite a marginal year-on-year decline in quarterly revenue.
Key Highlights
Full-year FY26 Net Profit jumped 116.6% to ₹66.13 crore compared to ₹30.53 crore in FY25.
Annual Revenue from Operations grew to ₹650.27 crore in FY26 from ₹599.51 crore in the previous year.
Finance costs significantly reduced to ₹29.98 crore in FY26 from ₹36.95 crore in FY25, aiding bottom-line growth.
Q4FY26 Net Profit stood at ₹21.70 crore, up from ₹20.26 crore in Q4FY25.
The company reported an exceptional item loss of ₹3.60 crore during the quarter and year ended March 31, 2026.
👀 What to Watch
The sharp increase in profitability and reduction in interest burden are strong positives for the company's valuation; investors should monitor if the company can sustain these improved margins and accelerate revenue growth.
Wanbury's Patalganga Site Receives Zero Observations from Korea FDA (MFDS)
Wanbury Limited has successfully completed a regulatory inspection by the South Korean Ministry of Food and Drug Safety (MFDS) at its Patalganga facility. The three-day inspection, conducted between April 7 and April 9, 2026, concluded with zero observations, confirming full cGMP compliance. This adds to the company's track record of clean inspections, following zero observations from the USFDA for Patalganga and Anvisa for its Tanuku plant. Furthermore, the company is expanding its API manufacturing capacity with a new block in Andhra Pradesh currently under validation.
Key Highlights
Patalganga facility cleared the MFDS (Korea FDA) inspection with zero observations.
The 3-day regulatory audit was conducted from April 7 to April 9, 2026.
Both Patalganga and Tanuku sites maintain USFDA compliance with a history of zero observations.
A new state-of-the-art manufacturing block for APIs is being commercialized at the Andhra Pradesh site.
👀 What to Watch
The successful audit strengthens Wanbury's position in regulated international markets and reflects high manufacturing standards. Investors should monitor the commercialization of the new API block in Andhra Pradesh as a potential catalyst for revenue growth.
Wanbury Limited FY26 Compliance Report: Resolves Past Board Issues & Promoter Demat
Wanbury Limited's Secretarial Compliance Report for FY 2025-26 indicates the resolution of several significant past governance lapses. The company has successfully dematerialized 100% of promoter holdings and restored the required board and committee compositions, which previously led to fines exceeding ₹51 lakh. While a minor delay in filing the September 2025 shareholding pattern resulted in a ₹42,480 fine, the company is now largely in compliance with SEBI regulations. This transition suggests an improvement in administrative discipline compared to previous years.
Key Highlights
Paid a fine of ₹42,480 for delayed submission of the shareholding pattern for the quarter ended September 30, 2025.
Achieved 100% dematerialization of promoter shareholding, resolving a previous deficiency where only 76.74% was in demat form.
Restored Board of Directors to the required minimum of 6 members and Audit/NRC committees to 3 members by January 2025.
Settled substantial historical fines including ₹37.99 lakh for board composition and ₹10.57 lakh for NRC composition lapses.
Confirmed compliance with Secretarial Standards (SS) and all other major SEBI regulations for the review period.
👀 What to Watch
Investors should view the resolution of past governance issues as a positive step, but remain cautious due to the company's history of administrative delays and fines. Monitor future filings to ensure the company maintains its restored board and committee structures consistently.
Wanbury Launches New Pediatric Products to Target ₹861 Cr Cold Preparation Market
Wanbury Limited has launched Coriminic CPM Drops and Coriminic NS Nasal Drops to align with recent DCGI regulations restricting fixed-dose cold combinations for children under 4 years. This strategic move allows the company to protect and grow its presence in the ₹861 crore Cold Preparation Liquid market. By introducing standalone formulations that avoid restricted combinations, Wanbury is positioning itself as a first-mover in safer pediatric care. The launch is expected to consolidate the company's market share in the fast-growing pediatric therapeutic segment.
Key Highlights
Launched Coriminic CPM Drops and Coriminic NS Nasal Drops specifically for pediatric use.
Strategic response to DCGI restrictions on Chlorpheniramine + Phenylephrine combinations for children under 4.
Targets a significant share of the ₹861 crore Cold Preparation Liquid market in India.
First-of-its-kind India-focused initiative to reposition Chlorpheniramine in a safer, regulation-aligned format.
Strengthens the established Coriminic brand portfolio through localized and non-systemic relief options.
👀 What to Watch
Investors should view this as a proactive move to safeguard revenue from regulatory risks in the pediatric segment. Monitor the company's ability to gain prescription share from physicians transitioning away from restricted fixed-dose combinations.
